Picornavirus Flashcards
Picornaviruses - PERCH
Poliovirus Echovirus Rhinovirus Coxsackievirus HAV
Structure of Picornavirus
Non-enveloped
+ stranded ssRNA, linear
All are enteroviruses (fecal-oral spread) except for Rhinovirus, which is acid labile
Polio vaccine (Sabin)
Oral, live-attenuated vaccine - trivalent vs. serotypes 1, 2, and 3
Induces mucosal immunity (IgA) as well as systemic (IgG/IgM)
1 / 2.5 million associated with Vaccine-Associated Paralytic Polio (VAPP)
Not used in the US; contraindicated for immunocompromised patients
Polio vaccine (Salk)
Injectable, inactivated, trivalent vaccine effective vs. serotypes 1, 2, and 3; exclusive use in US with 3 doses at ages 2, 4, and 12 months
Induces systemic IgG / IgM response; poor mucosal (IgA) response
Absence of live virus precludes possibility of reversion; can be given to immunocompromised patients
HAV Vaccine
Oral, live/attenuated vaccine
Induces mucosal immunity (IgA) as well as systemic (IgG / IgM)
1 / 2.5 million result in Vaccine-Associated Paralystic Polio (VAPP) via reversion
Not used in US; contraindicated in immunocompromised
Hand, Foot, and Mouth Disease
Caused by Coxsackie A infection
Presents in young children with fever, anorexia, malaise, sore throat, and vesicles on hands and feet; self-limiting
Diseases associated with Enterovirus infection
Asceptic meningitis
Myocarditis (esp. Coxsackie B - dilated cardiomyopathy)
Hemorrhagic conjunctivitis
Acute flaccid myelitis (Enterovirus D68)
Non-specific fever / rash (esp. in summer months)
Poliovirus - Pathogenesis
Infection occurs via ingestion of contaminated food or water; primary replication occurs in the pharynx, small intestine, and lymphatic tissue; primary viremia seeds infection to skeletal muscle where secondary replication occurs
CNS infection occurs via secondary viremia across the BBB or via retrograde axonal transport of virus up skeletal motor neurons
Causes destruction of motor neurons in the anterior horn of the spinal cord
Poliovirus - Presentation
90-95% asymptomatic / inapparent
5% minor URI
1-2% asceptic meningitis
0.1% flaccid paralysis
What was the WHOs original goal for eradication of polio?
Goal set in 1988 to eradicate polio by 2000
Polio eradication strategy
- Routine immunization with OPV
- Additional doses of OPV during National Immunization Days
- Acute flaccid paralysis surveillance
- Polio-free certification after 2-3 years without detection of circulating WT virus
- Laboratory containment of OPV and WT strains
- Stop OPV 3 years after certification
National Immunization Days
Immunization of every child < 5 years with 2 doses OPV regardless of prior vaccination status
Catches kids who haven’t been vaccinated and boosts immunity in prior vaccinees
How is surveillance of AFP performed?
Isolation and culture of virus from stool sample of affected patient; culture must grow cytopathic strain
Ab or ELISA assay of virus isolated from cytopathic culture to determine serotype
PCR distinguishes OPV vs. WT strain
Current status of polio eradication
2012: 222 global cases reported
WT OPV-2 and OPV-3 have been eradicated
Goal to end vaccination - 2019